Javier David Benitez Fuentes

🆕 New paper (SEOM Social Determinants WG): National survey of Spanish oncology professionals (n=258), >80% report SDOH influence cancer development/outcomes, ~68% link SDOH to treatment toxicity. Time, resources, protocols, and training remain barriers. link.springer.com/article/10.100…

Attending #ASCO26 ? We have some tips for you to make the most of this event. Both first-timers and veterans will find these useful. oncologybg.com/2026/05/22/are….

Don’t outsource critical thinking-@oncology_bg medscape.com/viewarticle/mo…

Excellent advice from Amol!

Attending #ASCO26 ? We have some tips for you to make the most of this event. Both first-timers and veterans will find these useful. oncologybg.com/2026/05/22/are…

Truth is not a popularity contest. Truth is truth even if zero people believe in it. medscape.com/viewarticle/mo…

I realize I might be offending some onco-celebrities with this new @Medscape video but this needed saying. medscape.com/s/viewarticle/…

@OncologyBGLab @lateuwen @ASCO Congrats @lateuwen

We are so proud to see our very own @lateuwen selected for the @ASCO 2026 Breakthrough Abstract Award. She will be presenting interesting results from our latest research. Congratulations to @lateuwen and all abstract and merit award winners. conquer.org/sites/default/…

People say that academic papers are only read by the coauthors (if any, and not always) and the author’s mom and trainees. Well, our latest @JCOOP_ASCO paper on how to read a clinical trial report seems to have been downloaded by more than 20K readers in less than a month of publication! ascopubs.org/doi/10.1200/OP…

@oncology_bg @JCOOP_ASCO Congrats Bishal, a must read for everyone

20K downloads in less than a month of publication. Has to be one of my most downloaded papers. Please read and prepare yourself for ASCO26 trials- ascopubs.org/doi/10.1200/OP… @JCOOP_ASCO

@sanidadgob La fortaleza del sistema de transplantes es que tiene una remuneración diferente (y mucho más elevada) para los profesionales que participan en ellos y que se prioriza sobre cualquier otro proceso o situación asistencial

Es curioso que se saque pecho de sanidad pública hablando de los trasplantes cuando tienen un sistema de gestión completamente diferente y ajeno al que tiene el SNS. Ojalá el SNS se gestionara como la ONT.

@hafaydeefe Buen punto

La centralización de la atención aumenta la toxicidad financiera y de tiempo ☝🏻 No es posible que en 2026 haya pacientes que sigan viajando 12 horas para recibir tratamiento.

New paper in @NatRevClinOncol ! We propose “time budgeting” as a new design principle for cancer care: treating patient time as a finite resource that should be measured, protected, and incorporated into care pathways & clinical trials. Because time is also a toxicity. ⏳

Common Sense Oncology at Queen's University is hiring a Program Officer! This position will play a key role in supporting CSO’s Canadian and global projects, and in helping to advance our research, knowledge mobilization, and advocacy initiatives. This is an exciting opportunity to be part of a passionate team working to spark patient-centred change in our cancer care systems. Because we believe that by working together, we can create a better world for people with cancer and their loved ones. If this mission is important to you, then come work with us! Go to the job posting: lnkd.in/e3rh2KTN #CommonSenseOncology #CancerCare

That was the right decision. medscape.com/viewarticle/wh…

@oncology_bg @FDAOncology Looking forward to read it 😄

Today @FDAOncology issued one wrong and one right approval. pCR is a prognostic marker not a predictive marker of treatment benefit. Drug approval based on pCR is not science based. Additionally, DB11 is a classic case of overpowered trial. They failed to meet their own stated goal of 15% improvement in pCR but this 11% difference was nevertheless significant because of overpowered trial. Approval of neoadjuvant TDXd based on DB11 is not an evidence based decision. For more on this, watch this video- medscape.com/viewarticle/be… However approval of adjuvant atezolizumab based on ctDNA is right. There is a difference between these two. Prognostic vs predictive biomarkers. Many people don’t understand this difference. We have a paper coming out soon to explain this.

Emails that make us happy and provide us meaning 🥰

🔴 Osakidetza sube a 59.000 euros el primer sueldo médico para retener al #MIR 📝 La #sanidad vasca pagará 2.564 euros más de base a los residentes que acaben su formación y quieran seguir en #Euskadi buff.ly/q16PLLv